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Abstract 
Next-Generation Sequencing (NGS) technology has advanced the field of personalized medicine 
by predicting effective treatments for cancer patients using genomic sequence data, including the 
detection of oncogenes (genes involved in cancer development). Simultaneous amplification of 
multiple DNA templates (referred to as polyclonal formation) is a primary disadvantage when 
preparing templates for NGS resulting in redundancies in DNA sequences or nonspecific noise in 
the sequencing. This study was conducted to compare DNA templates for sequencing prepared 
using two instruments the Thermo Fisher Ion Chef (IC) and Thermo Fisher OneTouch-2 (OT2). 
Six sequencing metrics obtained from 114 sequencing trials for evaluation: polyclonal reads, 
total sequencing reads, empty microcell well reads, no-template reads, useable number reads, and 
library number reads. A comparison of mean sequencing metrics between the IC and OT2 
methods established that for four of the six metrics, IC was the preferred operation for DNA 
template preparation due to the less polyclonal formation. 	
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Introduction 
Next-Generation Sequencing (NGS) revolutionized the field of personalized medicine by 
providing better health care outcomes for cancer patients through sequencing their cancer’s 
genetic changes and allowing for individualized treatment approaches. NGS impacted genomic 
medicine (personalized medicine) by providing a technology that could quickly sequence tumors 
(days instead of months). NGS allows simultaneous sequencing of millions of DNA fragments 
called massively parallel sequencing. These fragment sequences are then mapped (placed end-to-
end) using the human reference genome (Behjati & Patrick, 2013). The technique is used to 
rapidly detect single DNA mutations or more extensive mutations including gene fusions 
(translocation, chromosomal inversion), and somatic copy number variations (SCNV) 
subsequently used to design a treatment strategy (Koboldt et al., 2013). NGS technology has 
been increasingly employed in genomic medicine (Koboldt et al., 2013). 
Completion of the Human Genome Project (HGP), considered a breakthrough scientific 
achievement, mapped for the first time the vast majority of the human genome (complete set of 
DNA), allowing scientists to begin pinpointing the genes (also called oncogenes) involved the 
onset or progression of cancer (Harrow et al., 2012). Sequencing of these oncogenes by 
automated, big–dye methodologies was relatively slow compared NGS, which is orders of 
magnitude faster. HGP reported the first draft of the human genome in 2001 providing initial 
information about the human genomic landscape (Lander et al., 2001). The HGP determined the 
nucleic acid sequence order for almost all the base pairs in the human genomes. It also provided 
linkage maps indicating the location of known and proposed protein-coding genes (n = 20,000- 
25,000) (Lander et al., 2011). In 1990 the National Human Genome Research Institute (NHGRI) 
formed a collaboration with other global institutions to sequence the human genome by 2005, but 
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this project was completed earlier than expected in 2001. Approximately 99% of the genomic 
sequence was completed, the majority of the human genome is noncoding DNA, also referred to 
as junk DNA with unknown molecular function (Venter et al., 2001). It took about 11 years to 
get the first nearly complete human genome sequenced and made available to biomedical 
researchers. 
The HGP sequence is used as a baseline by researchers to align sequences derived by 
NGS sequencing of tumors. Understanding the particular cancer genome sequence has helped 
oncologists to develop personalized treatments for many patients. For example, if a patient is 
predicted, based on DNA sequence, to be resistant to a particular drug (chemotherapy) then a 
different compound could be administered. Many research studies have theorized that somatic 
mutations that frequently occur in cancers are involved in cancer progression (Merid et al., 
2014). Cancer is known to be a complex molecular disease caused by DNA mutation or 
epigenetic factors including environmental stimuli (Merid et al., 2014). Cancer is a 
heterogeneous disease with discoverable genetic variations among tumors. Specific genetic 
variants have been identified and linked with specific types of cancer (Kandoth et al., 2013). 
As we better understand the molecular genetic pathways involved in human diseases like 
cancer, scientists have identified an increasing number of genomic alterations (DNA mutations) 
that have potential roles in cancers (Rykunov et al., 2016). Accurate and rapid identification of 
DNA mutations is the reason NGS has become the platform of choice. Throughput capabilities 
and the quality of data are two important variables to consider when deciding on technology to 
use for diagnostic molecular testing. Rating the instruments performance may be based on three 
key criteria: sequencing throughput (read length of the DNA sequencing), the accuracy of data 
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(simultaneous sequencing of a single rather than multiple templates), and sequencing depth 
(DNA templates optimization or coverage sequencing).  
NGS technology has shown promise for classifying diseases based on genomic 
alterations, but ethical issues must be considered to maintain patient confidentiality. It is 
common for new emerging biotechnologies to raise ethical issues during its implementation. 
Currently, there is an enormous need for greater focus on how tumors acquire mutations that 
contribute to disease or drug resistance. Therefore there is a need to analyze genetic changes in 
tumors isolated from individual patients.  Patient consent before using a biospecimen in clinical 
research is mandatory (Beskow & Dean, 2008). Following consent, a patient’s confidentiality 
could be breached if sequence data was used for purposes other than testing (Beskow & Dean, 
2008). Genomic testing should never be shared without a patient’s consent. Because NGS 
technology is so powerful in that patient identifying sequence data are generated so quickly, 
additional care should be taken to protect these data. 
Genomic information derived from NGS may be useful in clinical trials accelerating the 
lengthy drug development process as well as enhancing its effectiveness by providing genomic 
data for the drug approval process (Amur et al. 2015). NGS can be a useful tool in drug 
discovery pipeline from preclinical studies to the clinical research. The Food and Drug 
Administration (FDA) supports through its Critical Path Initiative (CPI) strategies for driving 
innovation in genomic biomarkers (Hamburg & Collins, 2010). Additionally, identification of 
genomic information before treatment has the potential to spare patients from receiving therapies 
that will be ineffective against their tumors. For example, Oncotype Dx is a relatively new 
genomic test currently used to predict the chance of breast cancer spreading to another part of the 
body (metastasis). This genomic test is used to screen early or late stage tumor samples for 21 
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oncogenes to target therapy treatment (Sparano et al., 2015). Targeted therapy (targeting specific 
genes or receptors involved in cancer progression) approaches may provide a specific treatment 
for a particular patient by using the genomic information from his or her tumor contrasted with 
that of their normal healthy cells (Ha & Shah, 2013). Genomic testing (DNA sequencing) 
provides a plethora of information strives to understand the genetic involvements in diseases and 
identifies new approaches for efficient cancer treatments or predictive preventive care (Zhang et 
al., 2011). 
Development and use of reliable biological biomarkers for cancer progression is one of 
the strategies that FDA is encouraging pharmaceutical companies to employ to accelerate the 
drug development process. Biomarkers refer to biological markers that can be used as surrogates 
to measure disease formation and progression. Using genomic or molecular characterization to 
steer patients to the right drug at the right doses at the right time is the mission of personalized 
medicine. The success of personalized medicine depends on having accurate molecular 
diagnostic tests that identify patients who can benefit from targeted therapies (Hamburg & 
Collins, 2010). 
There are two complimentary components of personalized medicine the first is 
pharmacogenetics, which is the study of inherited gene variants and how the drug response 
varies in individuals including the function of biological transporters encoded by genes (Jain, 
2009). The second is Pharmacogenomics usually refers to the analysis of an array of genes that 
may determine a drug’s behavior as well as be considered as a systematic assessment of gene 
expression (Jain, 2009). The science of pharmacogenomics studies how the human genome 
influences drug response within a person or subpopulation. People display differential responses 
to a drug due to differences in genetic variations that affect gene expression or function of 
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proteins (often enzymes) targeted by a drug (Goldstein et al., 2003). Personalized medicine 
allows us to determine the right medical treatments for each patient by understanding the 
molecular genetic pathways of diseases. Personalized medicine is still an emerging field that is 
facing many challenges particularly in drug regulatory policy, health insurance reimbursement, 
and integration into clinical practice (Devon et al., 2015). 
In the conventional medical approach to development, a drug is administered to people 
and then health care professionals monitor its safety and efficacy. Some may have a significant 
response to a drug, and some may have a minor response. There are many factors affect how 
people respond to the drug. Notably, some people may absorb, metabolize, and eliminate drugs 
differently than others due to genetic mutations or variations, liver enzyme function, aging, 
accumulation of the drug, lifestyle, environmental factors influence, etc. One objective of 
personalized medicine is to decrease adverse effects while maximizing an individual’s 
therapeutic response to a drug by using NGS. Classifying diseases based on genetic mutations or 
molecular genetic screening may help in defining more effective treatment approaches. Drugs 
usually interact with the cellular signaling pathways. Specifically, if an altered gene encodes a 
modified protein, it may affect drug absorption in the body, or may even cause the formation of a 
toxic chemical, which could have an impact on human safety (Goldstein et al., 2003).). 
In this study, the focus was on two next-generation operations that prepare DNA 
templates (sequencing the desired region of DNA segment) for sequencing primarily through 
amplification. Two different operations or instruments used for DNA template sample 
preparation during library creation are the OneTouch-2 (OT2) and the Ion Chef (IC). Both 
instruments employ the same strategy for sample template development. The workflow of IC is 
to prepare an amplification of DNA template, perform emulsion polymerase chain reaction 
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(emPCR), purify samples and load the sample into the biochip (sequencing biochip). In this 
procedure, magnetic beads attach to the target DNA template only. Therefore, the IC prepares 
the template for sequencing and loads it on the sequencing biochip.  The latter step is not 
performed by the OT-2 operation. 
In this study, the emphasis was on a significant problem in DNA template preparation, 
polyclonal amplification, that occurs during library creation generated from cancer cell DNA by 
comparing the work performance of two instruments OT2 and IC. The study was designed to 
compare sequencing performance of the DNA templates and the consequence of high-percentage 
polyclonal reads when sequencing 131 oncogenes using the fully-automated IC versus the semi-
automated OT2. The hypothesis was that the IC operation would have less polyclonal formation 
than the OT2 instrument. Preliminary observations support this hypothesis.  I also hypothesized a 
negative association between high polyclonal percentages outcome and overall average total 
DNA sequencing throughput. 
Polyclonal amplification (DNA template duplications) occurs during DNA library 
preparation and can have a substantial impact on the sequencing outcome (Perrott, 2011).  
Polyclonal formation interferes with sequencing results by increasing sequencing duplications or 
simultaneous signaling. Sequencing noise occurs when polymerase chain reaction (PCR) 
duplications affect DNA sequencing reads and causes unreadable sequencing information. 
Polyclonal formation before DNA sequencing can negatively impact DNA sequencing shown to 
results (Schweyen, Rozenberg, Leese, 2014). It is common for a laboratory to repeat analysis of 
a sample due to many polyclonal reads stochastically reducing sequence coverage. The goal of 
this study was to make an assessment of the extent of polyclonal formation and determine which 
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methods of template creation would maximize the coverage of the genome or sequencing output 
of the PGM. 
In this study, PCR used for amplification of a DNA template. The amplification step is 
necessary to have enough material to sequence. PCR is a lab molecular technique used to 
amplify a single target DNA template. Another type of PCR that is commonly employed in NGS 
is emulsion PCR (emPCR), and it refers to clonal amplification in droplets of oil-aqueous 
solution (reaction bubble) that contains the target DNA template attached to beads. These 
magnetic beads are designed to attach to the target DNA template that will eventually be 
sequenced. NGS sequencing requires four major workflow steps:  nucleic acid extraction; library 
construction (DNA template preparation with IC or OT-2); sequencing; and analysis 
(bioinformatics). DNA extracted from tumor biospecimens is obtained from patients and used for 
DNA template library preparation before sequencing. DNA library preparation or “library 
creation” is an essential lab technique that attaches tagged DNA segments to the sequence being 
interrogated. Successful sequencing requires a sufficient amount of DNA (fewer PCR 
duplication reads) with sequence adaptors (“barcodes”) added to particular ends of the DNA 
segment. These barcodes act as a red flag to distinguish which DNA region needs to be 
sequenced. They are also a useful tool in data analysis for alignment purposes to identify the 
DNA sequence fragments since NGS produced millions DNA segments reads that need to be 
aligned with the reference human genome.  
In this study, six different metrics of performance were obtained from the PGM run 
summary sequencing reports and used to evaluate sequencing quality: polyclonal reads, total 
sequencing reads, empty microcell well reads, no-template reads, usable reads and library 
number reads. Polyclonal reads refer to similar DNA template fragments attaching to the same 
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bead during library creation causing redundancies in the sequencing results data. Total 
sequencing reads or total reads relates to the overall number of successful DNA sequencing 
outcomes. Empty microcells or “empty well reads” refers to an empty well (no bead with DNA) 
on the biochip-318 arrays. No-template reads refer to microcell wells that had beads but didn’t 
have DNA template attached. Usable reads refer to the number of successful DNA templates 
sequenced. Library number reads relates to an overall number of library creations during sample 
DNA templates preparation. A total of 114 pre-run sequencing events from PGM servers were 
selected to provide study data. Simple random sampling method was used to selected data in this 
study. The selected samples had assigned a Paradigm Cancer Diagnostics (PCDx) number for 
sample identification. 
The Thermo-Fisher OT2 instrument was first introduced in 2011 for sample template 
preparation for sequencing exclusively with the Ion Torrent Platform. The OT2 uses an 
amplification protocol similar to the IC, but it does not have the enrichment or chip loading 
capabilities built into the instrument. The OT2 system contains two modules: the One Touch ES 
enrichment and OT2 instrument. OT2 requires manual pipetting after emPCR for template 
sample preparation. When samples processed through emPCR with OT2 instrument protocol, 
they need an enrichment lab process for selecting the beads that contained the DNA templates. 
Following enrichment, the reaction is manually pipetted into the biochip. Each biochip has 5.5 
million microcells available to accept beads (with DNA template). Therefore, the OT2 is a semi-
automated instrument that does clonal amplification but does not have the capacity to load the 
biochip. Enrichment refers to a wash step for the beads also called Ion Sphere Particles (ISPs) 
that removes leftover primers and deoxynucleotide triphosphate (dNTPs) from the PCR process. 
Figure 1 map out the reaction steps in the process of DNA templates preparation before DNA 
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sequencing. In contrast, when processing the sample with the IC, the sample enrichment step is 
automatically performed during the processing. Sample DNA template development in the semi-
automated OT2 requires more manual preparation time before loading the sample into the 
instrument and has no capacity to load biochips. 
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Figure 1. Emulsion PCR for DNA library preparation. There are three major steps in emPCR: 
denaturation; annealing; and extension. During DNA template preparation emulsion oil is mixed 
with the DNA library (aqueous solution) and PCR reagent (plus beads) to achieve a clonal 
amplification of single DNA molecules that contains these elements (DNA library, PCR 
reagents, beads). The first step in the reaction is denaturation (separation of DNA double strands) 
from each other at a specific temperature. After denaturation, the temperature is reduced to 
allowed primers (short synthetic strands of DNA) to attach to the long-strand DNA or beads 
(annealing), reverse strand anneals to adaptor site on the beads where primer anneals to forward 
strand. Extension refers to making a copy of the DNA; dNTPs are added to primers by DNA 
polymerase to make a complementary strand of DNA. Note. From “Emulsion PCR” by A. 
Vierstraete, 2012 (http://binf.snipcademy.com/lessons/ngs-techniques/emulsion-pcr). Copyright 
2016 by binf-snipcademy. Reprinted with permission. 
 
The semiconductor sequencer PGM provides DNA sequencing fast and in a cost-efficient 
manner. During DNA synthesis hydrogen ions are released when a new nucleotides {adenine 
(A), guanine (G), cytosine(C), thymine (T)} added to the target DNA strand. Semiconductor 
sequences detect the release of the hydrogen ion, and then software translates that into a DNA 
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sequence. During the sequencing process, the PGM reads the chemical changes in the biochip. 
Figure 2 showing the process of DNA sequencing by synthesized one strand of the DNA 
template.  There is a sensitive layer located at the bottom of the microcell of the biochip, which 
converts pH (a measure of hydrogen ion concentration) change into voltage. This voltage at 
specific times determines which base pairs added during primer extension (copying of the DNA).	
 
Figure 2. Illustration of the biochip sensor in semiconductor sequencing (318 ion chip). 
Schematic cross-section of a single microcell well of the biochip where DNA copying reactions 
occur (A). When dNTP (A, C, G, and T) flows into the chip, a H+ released if there is base 
pairing (B) and the base is incorporated into the growing DNA chain. The pH of the solution will 
change (red signal) in this synthesis reaction when incorporation of a nucleotide occurs. An 
algorithm is used to convert (C) from full series of integration signals from the microcell well 
into sequencing reads. Green color (A), blue color(C), red color (T), gray color (G). Figure 2. 
Semiconductor pH sensor device. Adapted from “Progress in ion torrent semiconductor chip 
based sequencing” by B. Merriman and J. Rothberg, 2012, Electrophoresis, 33, p. 3401. 
Copyright 2016 by John Wiley and Sons (Rights Link). Reprinted with permission. 
 
The PGM system works by synthesizing a complementary DNA strand in the presence of 
one of four nucleotides at a time (wash steps occur between the addition of each new nucleotide). 
Figure 3 below show the PGM used in NGS. The PGM takes advantage of measuring the release 
of H+ ions whenever there are two complementary base pairing bonds or matches during the 
covalent bond formation (A-T and G-C or vice versa T-A and C-G) a H+ ion is released. If a 
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nucleotide did not incorporate into the growing DNA strand, then there would not be any 
changes in pH and there wouldn’t be a signal generated. Appendix D shows the overview of 
PGM steps for sequencing data generated in NGS as well as the biochip 318 that commonly used 
in molecular laboratory.  	
 
Figure 3. Ion Torrent Personal Genome Machine (PGM™). The PGM platform used for 
sequencing DNA. The PGM picks up electrical signals produced by the chemical changes in the 
biochip (pH) and this signal is converted into the sequence data. Note. From “Ion Personal 
Genome Machine® (PGM™) system” by Thermofisher Scientific 
(https://www.thermofisher.com/us/en/home/technical-resources/contact-us.html). Copyright 
2016 by Thermo Fisher Scientific. Reprinted with permission.  
  
The biochip advance technology commonly used in NGS. Figure 4 show the detection of 
H ion released during the sequencing process. Figure 4 illustrated a close look for a single 
microcell well in the biochip 318 used in the PGM. 
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Figure 4. Measurement of H+ during sequencing reactions with a PGM.A microcell well of the 
biochip (right) is sequences DNA by monitoring the H+ release. Enzymatic addition of dNTPs or 
nucleotides to the DNA chain causes a H+ ion release. These chemical changes are transformed 
into an electrical signal indicating the addition of a specific nucleotide. Left image, Figure 1b. 
Semiconductor pH sensor technology. Adapted from “Progress in ion torrent semiconductor chip 
based sequencing” by B. Merriman and J. Rothberg, 2012, Electrophoresis, 33, p. 3400. 
Copyright 2016 by John Wiley and Sons (RightsLink). Reprinted with permission.  
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Research Design and Methodology 
Template preparation for NGS required five major lab procedures: nucleic acid extraction 
(DNA and RNA); library creation (barcode added to DNA template), PCR emulsion 
amplification (emPCR); enrichment; and sequencing. DNA and RNA extracted from cancer 
samples tissue processed in formalin-fixed paraffin embedded (FFPE) blocks. Nucleic acid was 
purified using Qiagen kit reagents (QIAamp DNA FFPE tissue kit) per manufacturer's 
instructions accessed from (https://www.qiagen.com/us/resources/resourcedetail?id=63a84dc7-
d904-418e-b71a-1521cf318e82&lang=en). Briefly, FFPE sections were incubated with an excess 
of xylene to dissolve and remove paraffin wax. The sample was spun in a centrifuge (20,000 x 
gravity (g) for 2 minutes). The supernatant removed and 1 ml of ethanol added to the sample. 
The sample was incubated at 37°C for 10 minutes before 180 µl of buffer reagent (ATL) was 
added to the sample with 20 µl of Proteinase K (mixed by vortexing). Samples were incubated 
again at 56oC for 3 hours before adding 2 µl of RNase. A combination of 200 µl of buffer (AL) 
and 200 µl ethanol (95%) was then added together to each sample. The lysate was transferred 
unto a QIAamp MinElute spin column for elution at (centrifuge at 6000 x g for 1 minute). The 
purified nucleic acid sample was quantified using a Qubit 2.0 Fluorometer to determine the DNA 
concentration. A Thermo Fisher Scientific protocol was followed to measure deoxyribonucleic 
acid concentration. 
A QIAgility liquid handling instrument (Qiagen, Inc.) was used for automated mixing of 
library creation reagents.  Briefly, 5 µl of DNA library primer stock was mixed with 5 µl of 
nucleic acid prepared above. Samples were transferred to a Bio-Rad Rotor-Gene for PCR 
amplification using the following conditions: 95°C (hold 5 minutes, one cycle), 95°C (15 
seconds, 18 cycles), 60°C (30 seconds). Immediately after PCR amplification, samples were 
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placed in a frozen block (-20°C). Twenty µl of pooled sample for each set (1- 4 libraries) were 
put in the thermal cycler after adding 8 µl ExoSAP (used to remove the leftover of PCR 
reagents). The mixture was briefly spun in a micro-centrifuge. The following temperatures 
conditions were set up for thermal cycles over one hour: 37°C for 45 min, (1 cycle), 80°C for 15 
min (1 cycle), and 4°C for 1 min. Amplification products were either transferred to the OT2 or 
IC instrument for completion of DNA template preparation. (Thermo Fisher Scientific Company 
User’s Guide instruction protocol (https://tools.thermofisher.com/content/sfs/ manuals/ 
MAN0010902_PGM_HiQ_OT2_Kit_UG.pdf) was used for DNA templates development). The 
emPCR reactions were performed in the OT2 instrument before enrichment protocol using the 
Thermo Fisher Scientific protocol. Amplified DNA manually loaded onto 318 biochips. Figure 5 
maps out the steps for sample preparation in NGS.  
 
Figure 5. Showing the NGS workflow process for DNA sequencing of the cancer cells from 
DNA extraction of FFPE sections to sequencing with PGM. 
16 
Minitab 17 (statistical software, descriptive statistic) was used for performing statistical 
comparisons of means for the six metrics measured in this study. An independent t-test was used 
to compare the means. Institutional review board (IRB) approval was requested and appendix A 
is the IRB approvals letter for permission to do this study.  
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Results 
Polyclonal percentage outcome was assessed for an association with total sequencing 
reads or the coverage of DNA sequencing. Data indicated that optimal NGS occurs in the 
absence of identical DNA templates, attached to the same bead while preparing the sample for 
sequencing. There were 114 DNA specimens sequenced in this study. An independent-samples t-
test was used to determine if there were differences between IC and OT2 work performance 
means. Six-parameter variables were used to assess the DNA templates development 
performance (polyclonal reads, total sequencing reads, empty microcell well reads, no-template 
reads, useable number reads, and library number reads) for the two DNA library methods of 
DNA template preparation, IC, and OT2 (Appendix B). Four of six metrics measured identified 
IC operation as the preferred instrument for DNA template preparation for NGS with the PGM 
platform. Appendix A provides raw data for the metric performance variables used for evaluation 
of the study data. 
The polyclonal mean for IC was 31.82 (95% confidence intervals = 28.85, 34.80). The 
polyclonal mean outcome for OT2’s samples group was 43.09, 95% confidence intervals =39.70, 
46.48 refer to Figure 6. The polyclonal percentage was significantly higher (p = 0.032) than the 
average IC polyclonal percentage outcome indicating that there are more PCR duplications 
(polyclonal formation) for OT2 data.	  
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Figure 6. Showing the mean polyclonal formation when sample processed by OT2 was 
significantly (p = 0.032) higher than ICs mean. The horizontal line in the blue box indicates the 
median. The vertical line in the top of blue box refer to upper whisker (upper 25% of the points 
distribution) and the bottom vertical line from the blue box refer to lower whisker which 
represent the lower 25% of the points distribution.  
 
A significant difference (p <0.05) was observed between mean total numbers of 
transcripts sequenced for the two treatments. Samples processed through the IC protocol had 
significantly (p <0.05) higher PGM throughput or more overall DNA sequencing reads than the 
samples prepared with the OT2 instrument. The total DNA sequenced reads mean for the IC 
preparation was 3770605 (95% confidence intervals = 3520426, 4020784 (Figure 7). The total 
DNA sequenced reads mean for the OT2 preparation was 2850276 (95% confidence intervals 
=2600097, 3100455).  
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Figure 7. Showing the mean number of template sequenced by PGM. Mean total reads from 
samples processed for DNA template preparation in IC and OT2 operation. The horizontal line in 
the blue box indicates the median. The vertical line in the top of blue box refer to upper whisker 
(upper 25% of the points distribution) and the bottom vertical line from the blue box refer to 
lower whisker which represent the lower 25% of the points distribution.  
 
Mean empty microcells well (surface of the biochip without a DNA-carrying bead) in IC-
processed sample outcome was 33.89 (95% confidence intervals 30.021, 37.769) and the mean 
for the OT2’s samples was 21.6 (95% confidence intervals 29.23, 38.55, Figure 8). The two 
means of the empty microcells (OT2 and IC) were significantly different (p <0.05). 
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Figure 8. Showing the percentage of empty biochip surface. Empty microcell wells of the 
biochip that does not contain sample through automation loading (IC) verses manual loading 
(OT2).  Empty microcell wells indicate areas of the biochip that did not got filled with a bead. 
Each dot in graph represents a data point generated from NGS.  
 
Mean beads without DNA templates (no target DNA attached) was significantly (p 
<0.05) higher in IC-processed specimens than the OT2 processed ones. The IC sample mean for 
empty beads or no-DNA template was 9.85 (95% confidence intervals = 6.48, 13.22) and the 
average for OT2 samples was 1.825, (95% confidence intervals = 0.725, 2.924) refer to figure 9 
below.	
 
Figure 9. Showing the ISP (beads) without DNA templates processed through NGS. Beads 
without a DNA template discovered during NGS sequencing and dots represent data points. 
 
21 
The average for IC DNA library number was 72.71 (95% confidence intervals 69.61, 
75.80) and the mean for OT2 prepped samples were 59.825 (95% confidence intervals 56.73, 
62.91). A significant difference (p <0.05) was observed between IC’s operation for DNA library 
creation and OT2’s operation. Figure 10 shows the data distribution for library number detection 
during the DNA sequencing. 	
 
Figure 10.  Showing the DNA Library number outcome from NGS. Library number percentage 
outcome for IC and OT2 for DNA template preparation samples. Dots represent the data point of 
the empty beads or no-DNA template.   
 
The mean usable DNA library percentage outcome was 53.26 (95% confidence intervals 
50.78, 55.73) for IC, 39.47 (95% confident intervals 36.97, 41.92) for OT2 (Figure 11). A 
significant difference (p <0.05) was observed between IC’s operation for usable DNA library and 
OT2’s operation.  The usable DNA library percentage in IC operation was significantly higher (p 
<0.05) than the average OT2 percentage outcome. Appendix C showed an example of the 
summary reports generated by PGM. 	
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Figure 11. Showing the usable DNA library outcome form NGS. Mean usable library percentage 
for OT2 and IC prepared DNA libraries. Dots represent the data points for usable library number 
outcome.   
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Discussion 
The objective of this study was to investigate whether there is efficient DNA library 
preparation and the consequence of high-percentage polyclonal reads when sequencing 
targetable genes (screening for 131 oncogenes) using two different instruments. In this study, it 
was observed that only two minor (not statistically significant) differences in metric performance  
(the no-templates and empty microcell well) for IC versus OT2 instrument performance. 
However, these differences probably did not contribute to the final number of total DNA 
sequence reads. Data presented in this study showed that high polyclonal percentage in NGS 
negatively affected the overall average sequencing result reads, and that this impacted the depth 
coverage reads of target DNA sequenced. 
The study results supported the hypothesis that sample DNA template preparation 
performed by IC instrument was better (higher quality and quantity of DNA sequences) than 
sample DNA template preparations carried out by the OT2 protocol. High polyclonal formation 
by the OT2 significantly impacted the throughput of the PGM regarding DNA sequencing 
volume. As stated in the introduction, PCR duplicates can lead to false positive detection in NGS 
and affects the depth of sequencing outcome (coverage of alleles sequenced). Polyclonal 
formation occurs when two identical DNA fragments attach to the same beads during emPCR. 
Notably, the observation of the less polyclonal formation using the IC operation ensured a single 
DNA template per PCR emulsion mixture as the most probable. Usually, highly stable emPCR 
can yield a high percentage of beads, or optimal number of beads contained the DNA templates 
to be sequenced. Additional research will need to be conducted to find if there is a correlation 
between biochip scaling and algorithm sequencing for the Ion Torrent platform. It could be that a 
fraction of empty microcell wells contributed to better algorithm sequencing in PGM. 
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More research is needed to uncover other factors that may affect or influence overall 
coverage DNA sequencing results. It is possible that more beads aggregate (clump) when 
processed by the OT2 that generated more polyclonal formation. Also, the stability issue of the 
emPCR in OT2 operation could contribute to minimize the throughput of the PGM as well as the 
size of the micro-reaction generated through the emulsion PCR. 
The findings of this study are immediately useful for the Paradigm Company, indicating 
that for better efficiency of downstream sequencing we should use the IC format for emPCR 
instead of the OT2 platform. Study data showed that higher polyclonal percentage impacted the 
total sequencing reads (Figure 6). When there was a lower polyclonal formation efficiency of 
total DNA sequencing reads was higher.  
The study results also indicated the performance of emPCR in IC is more stable than 
emPCR processed in the OT2 instrument. Achievement of monoclonal amplification (beads 
attaching only DNA templates without duplications) observed during emPCR was at higher 
levels in the IC process than OT2. The stability of emPCR was more efficient in IC operation 
than OT2 operation that resulted in less polyclonal formation outcome. Also, the automation 
process could play a role by providing a highly stable emulsion that contributed to more efficient 
DNA sequencing. Another factor which could help forma stable emPCR that was beyond the 
scope of this study was on the size of the micro-reaction generated in the emPCR. 
This study data results also showed that DNA sequencing performance for templates 
prepared by the IC instrument, were maximized to give a better quality of sequencing than the 
samples prepared in OT2 for tumor DNA template preparation. Unmapped data in NGS (useless 
information) that may provide poor quality data in a sequencing run usually resulted in higher 
25 
polyclonal reads. This useless information may cause consume computing time filtering them out 
or removing them prior to bioinformatics data analysis. 
For no-template, results indicated that the OT2 performed better than the IC. However, 
this doesn’t substantially affect the final number of DNA sequencing reads. Additional research 
is needed to find out what factors influence bead recovery without DNA template. Also, the 
results indicated that the loading rate of samples into biochip was greater in OT2 samples 
processed samples than for IC –prepared samples. It could be that the manual pipetting hand put 
more pressure in loading the sample into the biochip. Also, it could be a final centrifugation of 
the sample before loading the sample into the PGM contributed and to better loading than 
automation operation. However, the manual pipetting or final centrifugation, once again, would 
probably not directly affect the overall DNA total sequencing reads according to data that 
showed the sequencing results were better than the sequencing results from the OT2 instrument 
(Figure 8).  
Research is also needed to explore the reasons that manually loading is better than 
automated loading of samples. There could be some challenges like centrifugation rates that 
prevent maximization of the loading rate of the sample during IC process into the chip. However, 
automated loading of the DNA sample template may perform better for completely loading the 
sample because of the potential of human errors accidently not loading the whole complete 
sample into biochip were reduced. Also, the metric of empty well in IC process did not show any 
significant impact on the throughput of the PGM.  
Despite the sample loading rate performance, where samples prepared in OT2 was higher 
than IC’s sample loading performance, the total DNA sequencing reads outcome was better with 
the IC preparation than the OT2’s preparation. There could be a barrier to bead recovery when 
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transferring the samples from the OT2 to the enrichment instrument. This study indicates that the 
polyclonal formation influences total DNA sequencing reads in NGS. 
The optimization of DNA sequencing by NGS is critical for reducing the DNA 
sequencing duplications (polyclonal) to increase the throughput of DNA sequencing outcome. 
Oncogenes that cause disease play a role in tumor cell progression and identification of these 
oncogenes will aid in genomic drug development to cure cancer (Pao et al., 2004). Efficient 
oncogene detection will also assist in the assessment of anticancer efficacy as well as reducing 
the time of clinical trial study or drug development. Oncogenes are involved in mutational 
processes, which lead to the metastatic stage of cancer (Rykunov et al., 2016). Some of these 
DNA mutations also allow cancer cells to escape being recognized or attacked by our immune 
cells through producing a particular protein to evade recognition (Rykunov et al., 2016). 
Identifying these oncogenic genes would aid us in fighting cancer through finding an effective 
treatment for patients. More extensive research studies need to conduct to link genomic medicine 
to the health care system. 
Despite the increased number of advances in drug development, the lack of drug response 
or efficacy for a significant proportion of people remains a major issue for drug effectiveness, 
particularly for oncology. For example, since 1998 only 10 drugs have been approved to treat 
lung cancer, whereas 167 other lung cancer drugs failed in clinical trial according to a recent 
report by PhRMA Public Affairs organization (2014). In 2011, FDA approved Crizotinib for 
patients with non-small lung cancer (NSCLCs) based on genomic testing of patients who 
contains the ALK (anaplastic lymphoma kinase) gene mutations in NSCLCs. Crizotinib was 
designed to target EML4-ALK by inhibitor ALK-positive oncogenic fusion gene to block tumor 
progression (Solomon et al., 2014). Progression-free survival was significantly longer in people 
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treated with Crizotinib than individuals in a chemotherapy control group; the objective response 
rate was 74% compared with conventional chemotherapy, 45% (Solomon et al., 2014). 
Crizotinib was associated with a greater reduction in lung cancer symptoms and more significant 
improvement in the quality of life (Solomon et al., 2014). An efficient sequencing for these 
oncogenes could help to improve the quality of patient life or maybe cure them from cancer. 
Drug development is a costly and lengthy process, which takes about 12 years of the 
clinical research study for a single drug marketing approval. An investigational drug must first 
pass the pre-clinical research study (Phase 0) as FDA requires that all investigational drugs must 
be tested on animals first before moving it into a human study (Phase 1). In essence, the genomic 
information or DNA sequencing is a useful tool to optimize drug development and accelerate the 
research process to get to the clinical endpoint of the investigational drug. A pharmaceutical 
company could use genomic information to predict cancer progression and provide more 
efficient treatment options to cancer patients. As stated earlier, NGS provides broad-spectrum 
analysis of DNA identifying chromosomal inversions, fusion genes, DNA mutations, DNA copy 
number variations, mRNA expression, and translocations of genes. Furthermore, genomic 
information could enhance health care quality and increase the efficiency of a patient’s 
treatment. Genomic medicine will not only match a medication that targets specific mutations in 
a patient but also can identify people who had the mutations for ineffective treatment response 
and kept them from taking the drug. For example, a KRAS mutation in colon cancer gives health 
care providers the potential option to determine the right medication for a patient and discontinue 
prescribing the same drug (Erbitux) found to be ineffective in patients with a mutated KRAS 
gene (Allegra et al., 2009). In other words, precision medicine will give the physician the option 
to match the DNA mutations that classify as driver cancer mutation to give a patient a particular 
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target treatment drug. Also, it can identify people with specific mutations and proteomic 
alterations (abnormal protein sequence or processing) that cause or affect them to have a 
different drug response. 
In the drug development industry it is very common to have drugs fail in a clinical 
research study either due to the safety or lack of efficacy (Hamburg and Collins, 2010). FDA 
regulations require a drug to be safe and effectiveness before approval. If the drug industry 
routinely used genomic information in a clinical trials research study, this could impact the 
quality of medicine as well as reduce the time of investigation and optimize the designed 
protocol of test screening by enrolling only patients with specific biomarkers rather than 
symptoms only. A small number of variations in genetic make-up influence how people response 
to a drug (e.g. DNA copy number variations, proteomic alterations, and gene fusions). An 
individualized medicine approach may play a crucial role in optimizing drug dosing and reduce 
the adverse effect of the medicine (Gorre et al., 2001). Advancing genomic medicine may also 
have a significant effect on the economics of drugs production and distribution. 
Personalized medicine not only helps in maximizing drug response but also enables 
physicians to avoid unnecessary and harmful treatments. Instead of developing a treatment then 
giving it to many people to see if it works, genomic screening information or molecular 
stratification could be used in advance to determine which patients will be more likely to benefit 
from the drug. If genomic sequence data is used to select a targeted therapy approach it may 
result in a better treatment for patients at the right time with the right dose of a drug.  Studies like 
the one described in this thesis will make sequencing for personalized medicine more efficient 
and less expensive.  
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Conclusions 
This study validated that polyclonal formation plays an important role by reducing the 
DNA sequencing reads or the performance of the PGM for cancer cells DNA sequencing. The 
higher rate of polyclonal formation for the OT2 method contributed to minimizing the 
performance of the PGM as measured by successful sequencing reads. The IC operation was 
efficient in DNA template development, which overall indicated a stable emPCR and good bead 
recovery that contributed to maximizing the DNA sequencing results. In order to have sufficient 
DNA sequencing using PGM platform there should be less polyclonal formation during DNA 
library creation. This study will contribute to personalized medicine by helping to detect 
oncogenes more efficiently. 
This study data established that the IC is preferred when preparing DNA templates for 
NGS due to less production of the polyclonal formations, and an efficient DNA library 
production contribute to effective final DNA sequencing reads. In addition, the IC consistently 
produced fewer polyclonal templates during emPCR, even when there were two metrics (empty 
microcell well and no-DNA template) that showed better performance by the OT2 instrument. 
Finally, the IC operation method is the preferred platform for DNA template preparation for 
NGS.  
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Appendix A: IRB approval letter for conducting the study. 
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Appendix B: The Thermo-Fisher Ion Chef and Thermo-Fisher OneTouch-2. 
 
	
The above picture is for Thermo-Fisher Ion Chef ™ used for DNA template preparation. Note. 
From “ Ion Personal Genome Machine® (PGM™) system” by Thermofisher Scientific 
(https://www.thermofisher.com/order/catalog/product/4484177?ICID=search-product). 
Copyright 2016 by Thermofisher Scientific. Reprinted with permission.     
 
 
The OneTouch-2 (OT2) for sample template preparation (right) and enrichment unit (left) that 
used to amplify and enrich DNA templates before loading into PGM for DNA sequencing. 
Note. From “Ion One Touch ™ 2 system” by Thermofisher Scientific 
(https://www.thermofisher.com/order/catalog/product/4474779?ICID=search-product) 
Copyright 2016 by Thermofisher Scientific. Reprinted with permission.    	  
37 
Appendix C: Example of Summary Report generated by Ion Torrent PGM sequencing 
software for an NGS run. 
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Appendix D: Ion Torrent biochips technology in NGS. 
	
	
	
Figure 4 and 5. Chip scaling and Informatics pipeline. Adapted from “ Progress in ion torrent 
semiconductor chip based sequencing” by B. Merriman and J. Rothberg, 2012, Electrophoresis, 
33,P. 3404 and 3413.Copyright 2016 by John Wiley and Sons (RightsLink). Reprinted with 
permission. 
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Appendix E: Metric variables used for analysis of influence of polyclonal on NGS.  
Appendix A: Metric variables used for evaluation of sequencing performance of IC and OT2 
templates. Blue variables represent IC data and green variables represent OT2 data. 
 
Poly.	 Poly.	 	Em.	 Em.	 T.	Reads	 T.	Reads			 N.Temp.		 N.Temp.	 L	ib.	 L	ib.	 Usab.	L	 Usab.	L	
16	 59	 43	 11	 3727144	 188170	 3	 0	 81	 77	 48	 31	
47	 15	 6	 52	 1285939	 344198	 0	 10	 84	 46	 47	 41	
24	 39	 27	 15	 4618076	 188170	 1	 0	 65	 86	 44	 20	
30	 44	 15	 13	 2792170	 536018	 0	 0	 82	 85	 48	 47	
16	 65	 36	 17	 4201664	 542199	 2	 0	 58	 69	 48	 83	
16	 27	 43	 17	 4619073	 3946	 3	 0	 84	 80	 48	 59	
22	 41	 69	 22	 2310154	 542199	 53	 3	 84	 82	 56	 48	
52	 14	 10	 68	 4482017	 559109	 0	 27	 84	 61	 37	 54	
23	 37	 26	 10	 5520951	 3956	 0	 0	 85	 82	 47	 52	
23	 53	 26	 1	 2881483	 559109	 1	 1	 85	 80	 49	 38	
20	 39	 27	 0	 3771806	 677654	 1	 0	 85	 89	 52	 54	
29	 55	 91	 16	 3543503	 687151	 58	 0	 86	 65	 48	 30	
20	 15	 46	 31	 3419140	 865185	 3	 0	 86	 48	 40	 41	
54	 47	 7	 11	 2347865	 912614	 0	 0	 87	 76	 35	 41	
18	 65	 30	 5	 4123390	 912614	 3	 0	 89	 82	 57	 28	
40	 52	 13	 15	 2521604	 931594	 0	 0	 81	 53	 49	 26	
41	 52	 10	 7	 1354992	 3220934	 0	 0	 67	 82	 53	 40	
49	 25	 10	 84	 1364657	 3308888	 0	 42	 57	 71	 70	 57	
33	 29	 19	 25	 1479156	 3543503	 0	 4	 81	 69	 54	 49	
34	 17	 19	 45	 1480372	 509542	 0	 6	 75	 46	 54	 39	
40 
Poly.	 Poly.	 	Em.	 Em.	 T.	Reads	 T.	Reads			 N.Temp.		 N.Temp.	 L	ib.	 L	ib.	 Usab.	L	 Usab.	L	
52	 30	 11	 18	 1496414	 3141117	 0	 0	 68	 71	 33	 50	
44	 70	 10	 7	 1546009	 1796591	 0	 0	 58	 78	 47	 23	
42	 43	 12	 22	 1644517	 4779951	 0	 0	 82	 61	 47	 35	
22	 16	 69	 50	 1932945	 3204810	 53	 6	 90	 52	 84	 45	
34	 36	 12	 15	 1945237	 4161907	 0	 0	 79	 86	 53	 55	
24	 45	 76	 19	 2003583	 1487148	 48	 0	 74	 58	 48	 42	
69	 50	 27	 13	 2357980	 2931643	 1	 0	 61	 58	 53	 39	
18	 15	 74	 32	 2358110	 2988692	 46	 3	 68	 59	 56	 46	
29	 51	 91	 10	 2369115	 3842791	 58	 0	 80	 60	 48	 41	
67	 19	 14	 31	 2406386	 3185633	 0	 1	 76	 60	 24	 50	
56	 14	 11	 54	 2438033	 3088224	 0	 4	 78	 61	 34	 33	
33	 23	 12	 16	 2566967	 4625177	 0	 0	 81	 61	 56	 57	
38	 18	 16	 49	 2746871	 5788493	 0	 6	 73	 61	 51	 51	
25	 31	 57	 33	 2844533	 3171902	 4	 1	 81	 61	 51	 39	
22	 32	 67	 29	 2908174	 2088083	 33	 1	 69	 61	 54	 42	
28	 22	 18	 21	 2913596	 3245131	 0	 0	 88	 61	 58	 55	
43	 42	 11	 16	 2913596	 3578035	 0	 0	 62	 61	 70	 45	
55	 49	 8	 19	 2979591	 3159315	 0	 0	 68	 61	 36	 35	
19	 65	 37	 21	 2979591	 5468838	 2	 0	 61	 62	 54	 7	
38	 47	 15	 18	 3041459	 5849615	 0	 1	 58	 63	 52	 44	
21	 35	 38	 28	 3058352	 4444907	 2	 0	 64	 64	 45	 35	
68	 54	 23	 15	 3069090	 2834369	 1	 0	 65	 65	 53	 37	
67	 55	 5	 14	 3082522	 366225	 0	 0	 84	 65	 70	 33	
55	 71	 8	 27	 3099400	 4461573	 0	 1	 82	 65	 36	 46	
41 
Poly.	 Poly.	 	Em.	 Em.	 T.	Reads	 T.	Reads			 N.Temp.		 N.Temp.	 L	ib.	 L	ib.	 Usab.	L	 Usab.	L	
22	 31	 1	 19	 3102120	 2658686	 1	 1	 84	 66	 50	 54	
16	 31	 36	 19	 3154839	 5258964	 1	 1	 84	 67	 50	 54	
33	 70	 80	 5	 3191111	 3466020	 48	 0	 81	 68	 47	 22	
18	 66	 70	 17	 3360650	 2211089	 31	 0	 87	 55	 67	 19	
20	 18	 50	 38	 3368599	 4621121	 6	 3	 68	 68	 55	 49	
46	 62	 18	 23	 3385869	 2659006	 0	 0	 72	 68	 43	 21	
20	 77	 73	 17	 2003583	 1487148	 23	 0	 74	 58	 48	 42	
41	 46	 12	 20	 2357980	 2931643	 0	 0	 61	 58	 53	 39	
15	 22	 48	 16	 2358110	 2988692	 5	 0	 68	 59	 56	 46	
18	 12	 56	 70	 2369115	 3842791	 16	 30	 80	 60	 48	 41	
19	 39	 42	 19	 2406386	 3185633	 2	 0	 76	 60	 24	 50	
31	 58	 13	 22	 2438033	 3088224	 0	 0	 78	 61	 34	 33	
14	 28	 45	 14	 3412419	 2030678	 1	 0	 87	 68	 63	 5	
0	 14	 86	 36	 3429187	 2710144	 40	 1	 61	 68	 52	 37	
2	 11	 72	 72	 3437062	 1571432	 27	 19	 87	 68	 49	 62	
21	 43	 48	 15	 3455296	 2800492	 5	 0	 57	 69	 48	 66	
25	 37	 23	 17	 3532977	 3746956	 0	 0	 81	 60	 50	 38	
20	 46	 40	 15	 3542274	 4882380	 3	 0	 63	 69	 59	 21	
42	 21	 13	 27	 3550358	 2206944	 0	 0	 57	 69	 50	 61	
34	 35	 87	 12	 3624667	 5036363	 84	 0	 71	 60	 75	 52	
28	 41	 22	 13	 3717449	 4080673	 72	 0	 63	 69	 75	 53	
34	 22	 87	 22	 3726083	 3651436	 33	 1	 80	 70	 46	 48	
28	 53	 27	 12	 3742113	 635254	 27	 0	 64	 70	 50	 47	
33	 55	 79	 17	 3772882	 3185820	 45	 0	 82	 71	 53	 39	
42 
Poly.	 Poly.	 	Em.	 Em.	 T.	Reads	 T.	Reads			 N.Temp.		 N.Temp.	 L	ib.	 L	ib.	 Usab.	L	 Usab.	L	
25	 43	 23	 15	 3772882	 3772587	 0	 0	 69	 71	 51	 48	
14	 19	 35	 32	 3788236	 1360051	 0	 2	 81	 71	 87	 56	
20	 30	 50	 25	 3867012	 3707029	 6	 1	 70	 71	 52	 43	
2	 29	 72	 21	 3868777	 2069477	 27	 0	 58	 71	 56	 52	
21	 34	 40	 22	 3883411	 5295435	 2	 0	 67	 72	 50	 32	
16	 54	 68	 15	 4026027	 1782042	 17	 0	 78	 72	 43	 31	
52	 15	 11	 45	 4030951	 3528697	 0	 2	 70	 72	 50	 48	
73	 15	 24	 56	 4035689	 4882380	 1	 16	 64	 72	 53	 50	
28	 36	 22	 30	 4044963	 3184642	 0	 2	 81	 73	 55	 43	
18	 27	 44	 16	 4236974	 550144	 3	 0	 70	 73	 84	 52	
33	 46	 23	 18	 4262882	 5145426	 0	 0	 53	 73	 46	 42	
33	 57	 0	 0	 4312548	 2596995	 0	 0	 74	 73	 45	 34	
31	 39	 4	 27	 4360090	 3054396	 4	 1	 81	 73	 86	 44	
31	 71	 0	 8	 4360726	 2030678	 0	 0	 87	 68	 63	 5	
36	 51	 0	 22	 3412419	 2710144	 0	 1	 61	 68	 52	 37	
22	 60	 35	 11	 3429187	 1571432	 2	 0	 87	 68	 49	 62	
23	 54	 51	 18	 3437062	 2800492	 4	 0	 57	 69	 48	 66	
18	 55	 60	 9	 3455296	 3746956	 18	 0	 81	 60	 50	 38	
24	 72	 18	 10	 3532977	 4882380	 1	 0	 63	 69	 59	 21	
23	 69	 25	 12	 4380399	 1739437	 1	 0	 83	 74	 40	 50	
18	 61	 40	 18	 4391232	 3822208	 6	 0	 50	 74	 52	 44	
17	 64	 39	 15	 4391232	 4456910	 3	 0	 63	 75	 52	 56	
27	 67	 19	 11	 4493318	 4625177	 0	 0	 81	 75	 53	 44	
40	 67	 14	 12	 4501500	 2191923	 0	 0	 77	 76	 59	 29	
43 
Poly.	 Poly.	 	Em.	 Em.	 T.	Reads	 T.	Reads			 N.Temp.		 N.Temp.	 L	ib.	 L	ib.	 Usab.	L	 Usab.	L	
20	 44	 67	 11	 4504740	 3499463	 22	 0	 63	 76	 51	 45	
57	 64	 11	 9	 4561055	 471043	 0	 0	 57	 0	 58	 19	
34	 70	 21	 11	 4563829	 4045339	 1	 0	 64	 77	 49	 30	
41	 15	 15	 54	 4563829	 3377443	 0	 6	 59	 50	 48	 27	
65	 57	 12	 12	 4573709	 4223708	 0	 0	 67	 77	 44	 32	
33	 34	 21	 69	 4574456	 4641896	 0	 3	 61	 77	 53	 31	
19	 41	 43	 14	 4674061	 3839094	 2	 0	 23	 53	 63	 15	
86	 33	 5	 21	 4765069	 3067548	 0	 0	 89	 77	 58	 17	
28	 43	 77	 21	 4799348	 2451206	 49	 0	 58	 77	 55	 30	
18	 23	 42	 29	 4804004	 4461573	 3	 1	 84	 78	 53	 23	
27	 76	 19	 10	 4811830	 2715554	 0	 0	 69	 78	 58	 19	
27	 67	 67	 7	 4837779	 3103272	 47	 0	 88	 78	 50	 22	
44	 66	 12	 15	 4847687	 2197951	 0	 0	 58	 78	 57	 47	
48	 41	 9	 14	 4853440	 2195294	 0	 0	 68	 79	 34	 26	
18	 33	 61	 21	 4893104	 2453734	 7	 0	 57	 0	 49	 17	
22	 43	 62	 21	 4903503	 1709281	 30	 0	 63	 80	 47	 44	
48	 80	 9	 0	 4941549	 2242032	 0	 0	 79	 20	 24	 31	
53	 69	 11	 9	 4974652	 3983784	 0	 0	 85	 80	 50	 14	
34	 60	 20	 7	 4994411	 4038780	 0	 0	 83	 80	 49	 46	
14	 60	 77	 7	 4380399	 3934044	 17	 0	 71	 25	 90	 53	
61	 61	 48	 17	 4391232	 1739437	 4	 0	 83	 74	 40	 50	
30	 36	 15	 16	 4391232	 3822208	 0	 0	 50	 74	 52	 44	
 
 
 
44 
Appendix F: Publisher Permission for use of Ion Torrent platform figures. 
	
	
	
